异甘草酸镁治疗抗肿瘤药物相关性急性肝损伤的成本-效果分析

Cost-Effectiveness Analysis of Magnesium Isoglycyrrhizinate Used In the Treatment of Antineoplastic Drugs-induced Acute Liver Injury

目的基于全社会角度,比较异甘草酸镁及还原型谷胱甘肽作为起始药物治疗抗肿瘤药物相关性急性肝损伤的成本-效果。方法回顾性收集2015~2016年某院住院治疗181例抗肿瘤药物相关性急性肝损伤患者的疗效和成本,建立决策树模型进行成本-效果分析,并采用单因素敏感性分析检验结果的稳定性。结果与还原型谷胱甘肽组比较,异甘草酸镁组期望成本较高,但期望效果更好,增量成本-效果比(ICER)为6 522.09元,敏感性分析显示结果可靠。结论异甘草酸镁作为起始药物治疗抗肿瘤药物相关性急性肝损伤具有成本-效果优势。

OBJECTIVE To evaluate the cost effectiveness of Magnesium isoglycyrrhizinate compared with Glutathione as initial treatment of antineoplastic drugs-induced acute liver injury. METHODS Retrospective data of efficacy and cost were collected from 181 patients with acute liver injury induced by antineoplastic in the People＇ s Hospital of Jieyang from 2015 to 2016. A decision tree model was constructed to analyze the data. The one-way sensitivity analysis was carried out to evaluate the stability of results. RESULTS Compared with Glutathione treatment group, Magnesium isoglycyrrhizinate treatment group gained more expect effective, but expect cost was higher, the incremental cost-effectiveness ratio （ICER） was 6 522.09 Yuan. The sensitivity analysis showed the result was stable. CONCLUSION Magnesium isoglycyrrhizinate for initial treatment of antineoplastic drugs-induced acute liver injury has cost- effective advantage.